Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
$34.62
-0.3%
$1.90
$1.44
$8.18
$24.24M0.13935,975 shs300 shs
Soligenix, Inc. stock logo
SNGX
Soligenix
$0.43
+10.3%
$0.61
$0.37
$4.20
$3.97M1.818.07 million shs681,062 shs
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
$54.99
$54.93
$14.91
$55.19
$1.34B0.03931,731 shsN/A
Teligent, Inc. stock logo
TLGT
Teligent
$0.03
$0.17
$1.60
N/AN/AN/A6,460 shs
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
$0.00
$3.90
$0.46
$37.45
$1K3.3425,375 shs5,685 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
-0.28%-0.09%-2.67%-2.73%+1,675.58%
Soligenix, Inc. stock logo
SNGX
Soligenix
+11.49%-1.91%-27.63%-29.99%-67.15%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.00%0.00%0.00%0.00%0.00%
Teligent, Inc. stock logo
TLGT
Teligent
0.00%0.00%0.00%0.00%0.00%
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Soligenix, Inc. stock logo
SNGX
Soligenix
0.1802 of 5 stars
2.02.00.00.01.10.00.0
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/AN/AN/AN/A
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
N/AN/AN/AN/A
Soligenix, Inc. stock logo
SNGX
Soligenix
N/AN/A$3.00602.58% Upside
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/A
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
$10K2,423.67N/AN/A$1.26 per share27.48
Soligenix, Inc. stock logo
SNGX
Soligenix
$840K5.28N/AN/A$0.24 per share1.78
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
$300K4,476.00N/AN/A$6.16 per share8.93
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/AN/A
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
$790K0.00N/AN/A$9.74 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/A
Soligenix, Inc. stock logo
SNGX
Soligenix
-$6.14M-$0.90N/AN/AN/A-731.94%-251.07%-49.94%5/20/2024 (Estimated)
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
-$94.66M-$6.77N/AN/AN/AN/A-111.88%-100.01%N/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
-$29.92M-$14.50N/AN/A-8,375.11%-177.06%-119.14%N/A

Latest SNGX, SRRA, ZSAN, TLGT, and EYEG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/15/2024Q4 2023
Soligenix, Inc. stock logo
SNGX
Soligenix
-$0.19-$0.16+$0.03-$0.16$0.20 million$0.25 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
N/AN/AN/AN/AN/A
Soligenix, Inc. stock logo
SNGX
Soligenix
N/AN/AN/AN/AN/A
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
N/AN/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/A
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
N/AN/AN/AN/AN/A

Latest SNGX, SRRA, ZSAN, TLGT, and EYEG Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/28/2024
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
Monthly$0.15724/1/20244/2/20244/5/2024
2/29/2024
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
Monthly$0.14863/1/20243/4/20243/7/2024
1/31/2024
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
Monthly$0.14762/1/20242/2/20242/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
0.01
3.07
3.07
Soligenix, Inc. stock logo
SNGX
Soligenix
0.40
1.55
1.52
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
0.02
21.27
21.27
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/A
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
N/A
1.61
1.61

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
64.16%
Soligenix, Inc. stock logo
SNGX
Soligenix
3.60%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
99.30%
Teligent, Inc. stock logo
TLGT
Teligent
N/A
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
N/A

Insider Ownership

CompanyInsider Ownership
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
58.20%
Soligenix, Inc. stock logo
SNGX
Soligenix
1.36%
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
44.10%
Teligent, Inc. stock logo
TLGT
Teligent
0.17%
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
2.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
14700,0005.28 millionNot Optionable
Soligenix, Inc. stock logo
SNGX
Soligenix
1310.38 million10.24 millionNot Optionable
Sierra Oncology, Inc. stock logo
SRRA
Sierra Oncology
10924.42 million13.65 millionOptionable
Teligent, Inc. stock logo
TLGT
Teligent
2,357N/AN/AOptionable
Zosano Pharma Co. stock logo
ZSAN
Zosano Pharma
404.90 million4.78 millionNot Optionable

SNGX, SRRA, ZSAN, TLGT, and EYEG Headlines

SourceHeadline
HOOK HOOKIPA Pharma Inc.HOOK HOOKIPA Pharma Inc.
seekingalpha.com - April 12 at 10:11 PM
Nachrichten - Weitere NachrichtenNachrichten - Weitere Nachrichten
wallstreet-online.de - January 9 at 2:39 PM
LISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy planLISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy plan
pbs.org - December 6 at 7:44 AM
Der Börsen-Tag: Diese US-Aktie stürzte nachbörslich abDer Börsen-Tag: Diese US-Aktie stürzte nachbörslich ab
n-tv.de - August 22 at 3:36 PM
East Bay Business NewsEast Bay Business News
bizjournals.com - May 18 at 9:49 PM
Mankind Pharma IPO opens on April 25, listing scheduled for May 9Mankind Pharma IPO opens on April 25, listing scheduled for May 9
moneycontrol.com - April 27 at 4:20 PM
Astellas PharmaAstellas Pharma
forbes.com - April 6 at 12:00 PM
Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis FoundationGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation
finance.yahoo.com - February 5 at 12:11 PM
FTC asks court to hold pharma bro Martin Shkreli in contempt for failing to abide by ordersFTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orders
washingtonexaminer.com - January 23 at 3:25 PM
Zosano Pharma Corporation (ZSANQ)Zosano Pharma Corporation (ZSANQ)
ca.finance.yahoo.com - November 5 at 6:33 PM
Now bank­rupt, Zosano sells off its drug de­liv­ery tech that once en­ticed No­vo Nordisk, Eli Lil­lyNow bank­rupt, Zosano sells off its drug de­liv­ery tech that once en­ticed No­vo Nordisk, Eli Lil­ly
endpts.com - October 13 at 11:22 AM
Bankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma GiantsBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants
msn.com - October 12 at 2:32 PM
Bankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of ClaimsBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claims
marketwatch.com - August 28 at 7:45 PM
East Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 million
bizjournals.com - August 27 at 4:10 PM
Zosano Pharma Corp (ZSANQ)Zosano Pharma Corp (ZSANQ)
investing.com - August 25 at 12:28 AM
East Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1MEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M
bizjournals.com - July 26 at 8:27 PM
A Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.A Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.
bizjournals.com - July 26 at 8:27 PM
Zosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8Zosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8
dbtnews.com - June 3 at 11:27 AM
Zosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSANZosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSAN
marketwatch.com - June 2 at 3:26 PM
Why Zosano Pharma Shares Are Getting Hammered TodayWhy Zosano Pharma Shares Are Getting Hammered Today
msn.com - June 2 at 3:26 PM
Zosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%Zosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%
seekingalpha.com - June 2 at 10:26 AM
Cash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSANCash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSAN
marketwatch.com - June 2 at 10:26 AM
East Bay migraine patch developer files for bankruptcyEast Bay migraine patch developer files for bankruptcy
bizjournals.com - June 2 at 10:26 AM
Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11
finance.yahoo.com - June 2 at 10:26 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AB Corporate Bond ETF logo

AB Corporate Bond ETF

NASDAQ:EYEG
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.
Soligenix logo

Soligenix

NASDAQ:SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Sierra Oncology logo

Sierra Oncology

NASDAQ:SRRA
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.
Teligent logo

Teligent

NASDAQ:TLGT
Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.
Zosano Pharma logo

Zosano Pharma

NASDAQ:ZSAN
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.